Biocept Inc (NASDAQ: BIOC)
Biocept is having a great day in the market today after announcing that the European Patent Office has awarded the company a patent. Today, we’ll discuss the details of the patent, how the market is reacting to the news, and what we can expect to see from BIOC moving forward.
BIOC Awarded A European Patent
Today the European Bulletin announced that Biocept has been awarded a patent from the European Patent Office for “DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS”. The patent awarded to the company specifically covers the use of antibodies in the capture of rare cells. One of the rare cells listed is circulating tumor cells. The capture of the cells is taken from blood and other biological fluids using Biocept’s microchannel capture device, a device that the company has also patented. In a statement, Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept had the following to say:
“The issuance of this patent further expands our international patent portfolio to include the use of antibodies in the capture of cancer cells in combination with our microchannel for which multiple U.S. and international patents have been granted. Our antibody cocktail is a key part of our patented, proprietary method to capture and analyze cells from a wide variety of tumor types. In addition, this patent expands our IP protection for the use of a simple blood sample and other biological sample types in obtaining valuable biomarker information that can be used by physicians to personalize the treatment of patients with cancer.”
How BIOC Reacted To The News
As investors, we’ve come to expect positive movement in the market following any positive news surrounding a publicly traded company. That’s exactly what we’ve seen in the market so far today. Currently (11:14), BIOC is trading at $2.07 per share after climbing 10.71% in the market so far today.
What We Can Expect To See From BIOC Moving Forward
Moving forward, I’m expecting to see more positive news out of Biocept. Ever since I started following the company, I’ve found it to be incredibly interesting. After all, when we talk about BIOC, we’re talking about a company that has found a way to diagnose cancer through a simple blood test. However, the diagnosis goes far beyond that. In fact, Biocept has been working to not only diagnose cancer in a non-intrusive way, but also to define the best ways to treat patients on a case by case basis using biomarkers that tell them more than we have ever known about the disease. While, like any innovation in medicine, this is likely to take time to become a major source of profit, I do believe that in the long run, BIOC is going to do incredibly well in the market.
What Do You Think?
Where do you think BIOC is headed and why? Let us know your opinion in the comments below!